Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CPS1 | P31327 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954438 | 0.89 | MAPT (0.55) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL2207253 | 0.89 | MAPT (0.55) | MAPTTSHREPHX2CNR1KDM4E | |
| SCHEMBL2516616 | 0.87 | CPS1 (0.54) | TSHRCNR1MEN1KMT2ACPS1 | |
| SCHEMBL29951438 | 0.85 | CPS1 (0.52) | TSHRCNR1MEN1KMT2ACPS1 | |
| SCHEMBL876134 | 0.83 | MAPT (0.58) | MAPTTSHREPHX2CNR1KMT2A | |
| SCHEMBL9886019 | 0.82 | CPS1 (0.46) | TSHREPHX2MEN1KMT2ACPS1 | |
| SCHEMBL20214134 | 0.80 | KDM4E (0.69) | MAPTTSHRCNR1KMT2AKDM4E | |
| SCHEMBL29953598 | 0.80 | KDM4E (0.69) | MAPTTSHRCNR1KMT2AKDM4E | |
| SCHEMBL4745686 | 0.79 | MAPT (0.57) | MAPTTSHREPHX2CNR1MEN1 | |
| SCHEMBL29897652 | 0.79 | MAPT (0.57) | MAPTTSHREPHX2CNR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-9321748-B2 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-26 | — | — | US | disclosed |
| US-9321748-B2 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-26 | — | — | US | disclosed |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| EP-2247597-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2009100171-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100171-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | MAPT 4677/4885TSHR 902/4885EPHX2 2772/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | MAPT 3237/4885TSHR 1142/4885EPHX2 2687/4885 |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | NFKB2, NFKBIA, AP1G1 | MAPT 3515/4885TSHR 1120/4885EPHX2 1300/4885 |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | MAPT 9/4885TSHR 4797/4885EPHX2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.